Healthcare provider profile · identity verified

Ricardo Castillo, DO

Allopathic & Osteopathic Physicians|Family Medicine · SAN ANTONIO, TX · NPI 1740287440

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Ricardo Castillo, DO received $142.57 in general payments during 2025 across 3 reported records.

Abbott Laboratories accounted for 77.3% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 3 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$142.57

3 reported records · 3 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Abbott Laboratories	Unresolved — no canonical attribution shown	$110.21	77.3%	1	2025
Exact Sciences Corporation	Unresolved — no canonical attribution shown	$16.86	11.8%	1	2025
Medtronic, Inc.	Medtronic, Inc. exact · evidence 2025-07-22	$15.50	10.9%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$142.57	3

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
ID NOW INSTRUMENT Normalized: id now instrument	Device	Abbott Laboratories	$110.21	1	2025
Source payment records 2025-10-08 · Abbott Laboratories · $110.21 · Open Payments source
The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit	Device	Exact Sciences Corporation	$16.86	1	2025
Source payment records 2025-02-26 · Exact Sciences Corporation · $16.86 · Open Payments source
INCEPTIV Normalized: inceptiv	Device	Medtronic, Inc.	$15.50	1	2025
Source payment records 2025-08-13 · Medtronic, Inc. · $15.50 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	547	184
Levothyroxine Sodium	Levothyroxine Sodium	447	144
Amlodipine Besylate	Amlodipine Besylate	379	137
Losartan Potassium	Losartan Potassium	346	124
Rosuvastatin Calcium	Rosuvastatin Calcium	297	109
Lisinopril	Lisinopril	264	88
Omeprazole	Omeprazole	195	73
Metformin Hcl	Metformin Hcl	167	58
Gabapentin	Gabapentin	159	64
Simvastatin	Simvastatin	146	49
Metoprolol Succinate	Metoprolol Succinate	144	52
Pravastatin Sodium	Pravastatin Sodium	134	49
Hydrochlorothiazide	Hydrochlorothiazide	126	47
Vitamin D2	Ergocalciferol (Vitamin D2)	123	48
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	119	19
Montelukast Sodium	Montelukast Sodium	110	40
Jardiance	Empagliflozin	101	28
Fluticasone Propionate	Fluticasone Propionate	100	45
Albuterol Sulfate Hfa	Albuterol Sulfate	96	45
Celecoxib	Celecoxib	92	35
Trazodone Hcl	Trazodone Hcl	91	30
Alendronate Sodium	Alendronate Sodium	88	36
Tramadol Hcl	Tramadol Hcl	86	43
Eliquis	Apixaban	85	28
Furosemide	Furosemide	83	40
Escitalopram Oxalate	Escitalopram Oxalate	82	38
Risedronate Sodium	Risedronate Sodium	82	30
Tamsulosin Hcl	Tamsulosin Hcl	82	36
Metformin Hcl Er	Metformin Hcl	76	32
Alprazolam	Alprazolam	75	17
Meloxicam	Meloxicam	73	34
Pantoprazole Sodium	Pantoprazole Sodium	73	25
Carvedilol	Carvedilol	72	27
Sertraline Hcl	Sertraline Hcl	70	28
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	69	20
Pioglitazone Hcl	Pioglitazone Hcl	69	25
Famotidine	Famotidine	67	27
Donepezil Hcl	Donepezil Hcl	56	23
Allopurinol	Allopurinol	55	20
Metoprolol Tartrate	Metoprolol Tartrate	53	20
Ezetimibe	Ezetimibe	52	19
Finasteride	Finasteride	49	18
Clonazepam	Clonazepam	48	15
Ciprofloxacin Hcl	Ciprofloxacin Hcl	46	38
Glipizide	Glipizide	45	16
Baclofen	Baclofen	43	26
Bydureon Bcise	Exenatide Microspheres	40	12
Clopidogrel	Clopidogrel Bisulfate	39	15
Duloxetine Hcl	Duloxetine Hcl	39	17
Ozempic	Semaglutide	39	suppressed
Spironolactone	Spironolactone	37	15
Januvia	Sitagliptin Phosphate	36	12
Tizanidine Hcl	Tizanidine Hcl	36	20
Trulicity	Dulaglutide	35	suppressed
Lovastatin	Lovastatin	33	suppressed
Azithromycin	Azithromycin	31	31
Memantine Hcl	Memantine Hcl	31	suppressed
Methylprednisolone	Methylprednisolone	31	30
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	30	14
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	30	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	29	13
Myrbetriq	Mirabegron	29	11
Mounjaro	Tirzepatide	28	suppressed
Solifenacin Succinate	Solifenacin Succinate	28	13
Clonidine Hcl	Clonidine Hcl	27	suppressed
Nifedipine Er	Nifedipine	26	suppressed
Glipizide Er	Glipizide	25	suppressed
Potassium Chloride	Potassium Chloride	25	suppressed
Temazepam	Temazepam	25	suppressed
Buspirone Hcl	Buspirone Hcl	24	13
Paxlovid	Nirmatrelvir/Ritonavir	24	23
Eszopiclone	Eszopiclone	23	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	23	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	22	18
Farxiga	Dapagliflozin Propanediol	22	suppressed
Ondansetron Odt	Ondansetron	22	14
Xarelto	Rivaroxaban	22	suppressed
Benazepril Hcl	Benazepril Hcl	21	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	21	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	21	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	21	suppressed
Ropinirole Hcl	Ropinirole Hcl	21	suppressed
Glimepiride	Glimepiride	20	suppressed
Lorazepam	Lorazepam	20	suppressed
Terazosin Hcl	Terazosin Hcl	20	suppressed
Amoxicillin	Amoxicillin	19	14
Folic Acid	Folic Acid	19	suppressed
Naproxen	Naproxen	19	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	18	suppressed
Hydralazine Hcl	Hydralazine Hcl	18	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	18	16
Pregabalin	Pregabalin	18	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	18	suppressed
Aripiprazole	Aripiprazole	17	suppressed
Citalopram Hbr	Citalopram Hydrobromide	17	suppressed
Ibuprofen	Ibuprofen	17	11
Nitroglycerin	Nitroglycerin	17	14
Valsartan	Valsartan	17	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	16	15
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	16	suppressed
Enalapril Maleate	Enalapril Maleate	16	suppressed
Ibandronate Sodium	Ibandronate Sodium	16	suppressed
Bupropion Xl	Bupropion Hcl	15	suppressed
Chlorthalidone	Chlorthalidone	15	suppressed
Clobetasol Propionate	Clobetasol Propionate	15	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Megestrol Acetate	Megestrol Acetate	15	suppressed
Mirtazapine	Mirtazapine	15	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	15	suppressed
Propranolol Hcl	Propranolol Hcl	15	suppressed
Raloxifene Hcl	Raloxifene Hcl	15	suppressed
Synthroid	Levothyroxine Sodium	15	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	15	suppressed
Amiodarone Hcl	Amiodarone Hcl	14	suppressed
Humalog Kwikpen U-100	Insulin Lispro	14	suppressed
Meclizine Hcl	Meclizine Hcl	14	11
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Rizatriptan	Rizatriptan Benzoate	13	suppressed
Benazepril-Hydrochlorothiazide	Benazepril/Hydrochlorothiazide	12	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	12	suppressed
Atenolol	Atenolol	11	suppressed
Felodipine Er	Felodipine	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Prednisone	Prednisone	11	suppressed
Rybelsus	Semaglutide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$142.57 · 3 records	Abbott Laboratories	ID NOW INSTRUMENT, INCEPTIV, The Cologuard Plus Collection Kit	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error